AEterna Zentaris (AEZS) Trading Up 67.7%

Shares of AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) were up 67.7% during mid-day trading on Wednesday . The stock traded as high as $2.27 and last traded at $2.18. Approximately 17,142,742 shares changed hands during mid-day trading, an increase of 5,647% from the average daily volume of 298,316 shares. The stock had previously closed at $1.30.

A number of research firms recently weighed in on AEZS. ValuEngine lowered shares of AEterna Zentaris from a “sell” rating to a “strong sell” rating in a research report on Monday, September 17th. Zacks Investment Research upgraded shares of AEterna Zentaris from a “hold” rating to a “buy” rating and set a $1.75 price target on the stock in a research report on Tuesday, October 9th. One analyst has rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $2.92.

The stock has a market capitalization of $21.37 million, a price-to-earnings ratio of -1.51 and a beta of 1.25.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last posted its quarterly earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.16. The firm had revenue of $0.17 million for the quarter. AEterna Zentaris had a net margin of 6.76% and a return on equity of 20.71%. Equities analysts expect that AEterna Zentaris Inc. will post 0.05 earnings per share for the current fiscal year.

AEterna Zentaris Company Profile (NASDAQ:AEZS)

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.

Recommended Story: Index Funds

Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with's FREE daily email newsletter.

Leave a Reply